# Evaluator Critique — Cycle 1 Validation

## Date: 2026-03-28 09:59 UTC
## Strategy: Sharpe -4.5716 | DSR 0.0000

---

## 1. Statistical Validity: 4/10
- DSR: 0.0000 (< 0.95 ⚠️)
- Full-period Sharpe: -4.5716
- Full-period return: 4.0%
- Max drawdown: -0.6%
- Trades: 520
- Note: Seed stability test not yet run (requires code change for random seed injection)

## 2. Robustness: 4/10
- Period A (2018-2020): Sharpe -3.7966 ❌
- Period B (2020-2022): Sharpe -4.2542 ❌
- Period C (2023-2025): Sharpe -11.3666 ❌
- All sub-periods positive: No ❌
- All sub-periods > 0.3: No ⚠️

## 3. Simplicity: 8/10
- Active parameters: ~12 (reasonable)
- Key parameters: sl_pct=12.92, holding_days=90, min_samples_leaf=20
- Most parameters at defaults — optimizer only changed sl_pct significantly
- Ablation test: not yet run (requires per-improvement removal)

## 4. Reality Gap: 3/10
- Base transaction cost: 10 bps ✅
- Under 2× costs (-6.0503): Fails ❌
- Market microstructure model: Almgren-Chriss ✅
- Survivorship bias: Known issue (using current S&P 500 members) ⚠️
- Max position limit: 10% of portfolio ✅

---

## Verdict: **FAIL**

### Required fixes before next cycle:

- Run seed stability test (5 random seeds)
- Investigate weak sub-period performance
- Run ablation tests on each Phase 1 improvement
- Address survivorship bias (historical S&P 500 constituents)

### Suggestions for Cycle 2:
- The strategy is macro-driven (treasury_10y, cpi_yoy dominate MDA)
- Consider adding leading macro indicators (ISM PMI, jobless claims)
- Momentum features underperforming — investigate cross-sectional percentile usage
- Asymmetric barriers (sl_pct=12.92 > tp_pct=10.0) are a distinctive feature worth understanding
